


**ICHNO** 20  
**ECHNO** 22



Final Announcement

The Joint International  
Congress on Innovative  
Approaches in Head and  
Neck Oncology (ICHNO)  
and the European  
Congress on Head and  
Neck Oncology (ECHNO)

3-5 March 2022  
Brussels, Belgium



**The joint International Congress on Innovative Approaches in Head and Neck Oncology (ICHNO) and the European Congress on Head and Neck Oncology (ECHNO) is taking place in Brussels, Belgium from 3 to 5 March 2022.**

The European Society for Radiotherapy and Oncology (ESTRO), the European Head and Neck Society (EHNS) and the European Society of Medical Oncology (ESMO) have the pleasure to invite you to participate in this congress.

This joint congress promises to provide a unique platform for the dissemination of the most relevant and cutting-edge science and innovation in the field of head and neck oncology. ICHNO and ECHNO, biannual congresses respectively, promote multidisciplinary in head and neck oncology.

This joint meeting will specifically cover the main following topics:

- └ New insights in the epidemiology and prevention of H&N cancer
- └ Oncogenesis, HPV related cancers, immunology and vaccination
- └ Updated results of practice changing randomised trials
- └ Multidisciplinary management of H&N cancers
- └ Molecular targeted therapies and molecular imaging
- └ Novel radiation and surgical treatments
- └ Towards individualised management of H&N cancer
- └ Robotic and minimally invasive surgery
- └ Reconstructive and salvage surgery
- └ Elderly patients, co-morbidities and their impact on management
- └ New insight in systemic treatments of H&N cancers
- └ Thyroid, nasopharynx cancers and rare H&N cancers
- └ Quality of life, supportive care and management of treatment side effects

The format of the meeting will include prestigious invited 'state of the art lectures'; lectures on the latest innovative approaches; proffered papers and poster presentations of new data in the field of head and neck oncology. The programme will be enriched by pro and contra debates and Interactive tumour board sessions

where the audience will have the possibility to participate and share their input via an electronic voting system. There will be also a special focus on presentations of new data from practice changing randomised trials. Ample time will be given for discussions to allow in-depth interaction among the various disciplines and the participants.

To stimulate multidisciplinary interactions among the various specialists, all the lectures, debates, tumour boards and proffered papers will be given in the same congress room.

It is hoped that the mix of a rich and challenging scientific programme coupled with the quintessential atmosphere of Europe's capital will convince you to attend the joint ICHNO-ECHNO 2022 congress.

With warm regards,

Chairpersons of the ICHNO-ECHNO 2022 congress




**Pierre Blanchard**  
ESTRO



**Wojciech Golusinski**  
EHNS



**Sjoukje Oosting**  
ESMO






# ICHNO | 20 ECHNO | 22

## Final Announcement

<b>Scientific and Organising Committees</b>	<b>6</b>
<b>Deadlines</b>	<b>6</b>
<b>Abstract Submission</b>	<b>7</b>
<b>Scientific Programme</b>	<b>10</b>
Thursday 3 March 2022	10
Friday 4 March 2022	11
Saturday 5 March 2022	12
<b>Awards</b>	<b>13</b>
<b>General Information</b>	<b>14</b>



# Scientific and Organising Committees

## SCIENTIFIC COMMITTEE

**Chairs** Pierre Blanchard (FR), Wojciech Golusinski (PL), Sjoukje Oosting (NL)

**Members** Paolo Bossi (IT), Mererid Evans (UK), C. René Leemans (NL), Ingeborg Tinhofer-Keilholz (DE)

## ADVISORY COMMITTEE FOR RADIATION ONCOLOGY

**Chair** Mererid Evans (UK)

**Members** Vincent Gregoire (FR), Florence Huguet (FR), Hans Langendijk (NL), Esat Mahmut Ozsahin (CH), Claire Paterson (UK), Krzysztof Skladowski (PL), Silke Tribius (DE)

## ADVISORY COMMITTEE FOR MEDICAL ONCOLOGY

**Chair** Paolo Bossi (IT)

**Members** Irene Brana (ES), Ana Castro (PT), Joël Guigay (FR), Lisa Licitra (IT), Jean-Pascal Machiels (BE), Ricard Mesia (ES), Petr Szturz (CH)

## ADVISORY COMMITTEE FOR SURGERY

**Chair** C. René Leemans (NL)

**Members** Andreas Dietz (DE), Philippe Gorphe (FR), Sefik Hosal (TR), Antti Mäkitie (FI), Gregorio Sanchez Aniceto (ES), Christian Simon (CH), Giovanni Succo (IT)

## ADVISORY COMMITTEE FOR HEAD AND NECK CANCER RELATED SCIENCES

**Chair** Ingeborg Tinhofer-Keilholz (DE)

**Members** Jean-Emmanuel Bibault (FR), Ruud Brakenhoff (NL), Robert Ferris (US), Keith Hunter (UK), Claus Andrup, Kristensen (DK), Roberto Maroldi (IT), Pierre Saintigny (FR), Susanne Singer (DE), Rieneke van de Ven (NL)

## Deadlines

**Abstract submission**  
13 October 2021

**Early registration**  
15 December 2021

**Late registration**  
2 February 2022

**Desk registration**  
as of 3 February 2022

# Abstract Submission

Abstract Submission Deadline: **Wednesday 13 October 2021 (23h59 CET)**

## GENERAL INSTRUCTIONS

The abstract submission for ICHNO-ECHNO 2022 will open early September 2021. **The submission deadline is 13 October 2021 (23h59 CET)**. Abstracts must be submitted online on the ESTRO website at [www.estro.org](http://www.estro.org).

**We highly recommend completing your submission early, otherwise authors may experience technical delays due to server overload.**

For questions regarding the online submission process, please e-mail [abstracts@estro.org](mailto:abstracts@estro.org).

## REGULATIONS

With the submission of the abstract for ICHNO-ECHNO 2022 congress, the corresponding (presenting) author:

- Accepts responsibility for the accuracy of the abstract and ascertains that all authors are aware of the content before submission
- Accepts to be the contact person for all correspondence related to the abstract and to inform the co-authors about its status
- Accepts to identify any financial interest in products or processes described in the abstract. This includes stock ownership, membership on any advisory boards, commercially sponsored research or any other substantial relationships.
- Certifies that the information to be reported is for exclusive presentation in the session to which the abstract will be assigned if accepted and that the information will not be presented as such at any commercially sponsored satellite symposia during the conference
- Abstracts are embargoed until 1 month prior to the congress, at which point the abstract book is published online and abstracts are included in the searchable programme. Should you wish for an abstract to be embargoed until the congress, please email [abstracts@estro.org](mailto:abstracts@estro.org) by 31 December 2021.

Abstracts must be submitted and presented at the conference in English. The Scientific Committee reserves the right to reject an abstract written in poor English.

Abstracts will be anonymised before review to ensure fairness and eliminate possible bias.

## ABSTRACT SUBMISSION

### Abstract format

**Topic category:** choose the topic category that refers to the main subject of the abstract. The Scientific Committee reserves the right to re-categorise the abstract. (*Available topics are listed at the end of the guidelines.*)

**Presentation preference:** authors should indicate the presentation preference (oral or poster). Please note that opting for a poster presentation would mean that your abstract will not be considered for presentation as an oral communication by the Scientific Committee. Please choose this option only in the event that you are not able to deliver a presentation at the conference (due to language limitations for example).

**Keywords:** authors are required to provide 1 to 3 keywords (different from category).

**Title:** Abstract titles should be brief and reflect the content of the abstract. The title (maximum 100 characters) is important since it focuses attention (it is the "showcase" for the presentation). Do not use capital letters in the title except for words that are always capitalised and do not use non-standard abbreviations. Prospective clinical trials should be identified as such in the title of the abstract (include The National Clinical Trial number when applicable)

**Body of the abstract:** Abstracts should be structured in such a way as to include (1) Purpose/Objective; (2) Material/methods; (3) Results (4) Conclusion.

### The online abstract submission procedure:

- The online abstract submission system will not accept abstracts that exceed 3,000 characters (body of the abstract, including spaces).
- The use of standard abbreviations is desirable. A special or unusual abbreviation must be placed (in round brackets) after the first appearance of the word for which it stands.
- Table and image: with their submission authors may include maximum two (2) uploads (tables or images) in JPG or PNG formats. These uploads are not included in the number of characters. The maximum pixel size of an image is 600(w) x 800 (h) pixel.
- Data table: authors may include one data table using the insert table icon (we advise not to copy-paste a

table into the body of the abstract). The characters in a data table are included in the overall number of characters allowed.

└ Equations: can be inserted in the text as images.

#### FURTHER INSTRUCTIONS FOR AUTHORS AND ABSTRACT SELECTION PROCESS

Abstracts submitted for presentation will be reviewed by an international panel of experts in the field of the subject. Abstract review criteria are based on clarity, supporting data, scientific rigour, potential significance, interest in the topic chosen and innovation or usefulness.

└ **Work in progress:** abstracts on research obviously not yet performed and results not yet obtained will be banned.

└ **Case studies** will not be considered (only if first in man)

└ **Encore abstracts:** papers already presented in another meeting will not be considered, unless the previous audience is distinct from the ICHNO congress audience (e.g. national meetings). Abstracts should include new information and not solely include materials **already published**.

└ **Similar abstracts:** if very similar abstracts are submitted by the same authors, the Scientific Programme Committee reserves the right to select only one of the abstracts and reject any others.

Abstracts will be selected for one of the following presentation formats:

Oral presentation: the abstract is selected for oral presentation at any of the proffered paper sessions.

Poster presentation: abstracts that have been selected for presentation in a poster format. The posters are grouped by topic and are displayed throughout the meeting.

#### Withdrawal of an abstract

Submitted abstracts can be withdrawn until 10 November 2021. (To withdraw your abstract, you should send an email to [abstracts@estro.org](mailto:abstracts@estro.org)). After this date, withdrawal of abstracts is no longer possible. Abstracts selected for oral / poster presentation should be presented at the meeting. If the first (presenting) author cannot attend the conference, they should assign a replacement and inform the ESTRO office of the replacement as soon as possible.

**Notification of outcome of abstract submission will be sent by email in early-December 2021.**

Please note that acceptance of abstract does not entitle to a complimentary registration. Presenting authors should register for the congress by 15 December 2021.

#### ABSTRACT SUBMISSION TOPICS FOR ICHNO-ECHNO 2022

1. Epidemiology and prevention
2. Imaging, radiomics and artificial intelligence
3. HPV or EBV related cancers
4. Innovative treatments
5. Minimal invasive and reconstructive surgery
6. Multidisciplinary management
7. Biology and molecular targeting
8. Immuno-oncology
9. Supportive care, quality of life, rehabilitation
10. Salivary gland, skull base, skin and thyroid cancers
11. Management of elderly or frail patients
12. COVID-19

# Join our ESTRO members community, share our Vision

*Radiation Oncology.*  
**Optimal Health**  
Together. **FOR ALL,**

- ESTRO VISION 2030 -

The ESTRO membership gives you the tools to improve your daily practice, develop your career and contribute actively to the progress of radiotherapy, for the benefit of all cancer patients.

As a member of ESTRO, and according to your membership category, you will benefit from many advantages, amongst others:

- **Conferences and Courses:** Access to webcasts, eligibility for grants and awards, valuable discounts on registration fees
- **Education:** Access to ESTRO E-Library, ESTRO publications and guidelines
- **Journals:** Access to *Radiotherapy & Oncology (Green Journal)* and open access journals (*ctRO*, *phiRO*, *tipsRO*), discount on publication fees
- **News:** Access to ESTRO newsletters
- **Societies:** Voting rights and eligibility to be part of the Board of Directors

ESTRO offers several levels of membership, individual and collective, with benefits tailored to the needs of each member and their level of involvement within the Society.

Find more details on [estro.org/Membership](https://estro.org/Membership)

To Find the ESTRO membership that suits you best, have a look at our [ESTRO Membership Tree](#).

**ESTRO**

## THURSDAY 3 MARCH 2022

09:00 -09:15	<b>OPENING REMARKS</b> <i>P. Blanchard (ESTRO) ; W. Golusinski (EHNS); S. Oosting (ESMO)</i>
09:15 -09:45	<b>KEYNOTE LECTURE 1</b> <b>The good and bad of TNM8</b> <i>Chairs: P. Blanchard, FR; W. Golusinski, PL; S. Oosting, NL</i> <i>Speaker: Brian O' Sullivan, CA</i>
09:45 -10:15	<b>KEYNOTE LECTURE 2</b> <b>Biomarker guided treatment and monitoring for Head and Neck Cancers</b> <i>Chairs: P. Blanchard, FR; W. Golusinski, PL; S. Oosting, NL</i> <i>Speaker: Ruud Brakenhoff, NL</i>
10:15 -10:45	COFFEE BREAK
10:45 -12:00	<b>SYMPOSIUM 1</b> <b>AI in Head and Neck oncology</b> <i>Chairs: R. Leemans, NL &amp; I. Tinhofer-Keilholz, DE</i> AI guided pathological diagnosis <b>F. Klauschen, DE</b> AI for better diagnosis and surgical treatment of Head and Neck cancer <b>Cesare Piazza, IT</b> AI for Head and Neck radiation oncology <b>Jean Emmanuel Bibault, FR</b>
12:00 -13:00	PROFFERED PAPERS 1
13:00 -14:30	LUNCH AND SATELLITE SYMPOSIUM
14:30 -16:00	<b>NEW DATA FROM RANDOMISED TRIALS</b> TBC
16:00 -16:30	COFFEE BREAK
16:30 -17:45	<b>SYMPOSIUM 2</b> Modern management of unknown primary Head and Neck tumours <i>Chairs: F. Huguet, FR &amp; C. Simon, CH</i> What has we learned from TORS mucosectomy in management of unknown primary <b>Vinidh Paleri, UK</b> Advances in pathology for unknown primary <b>Senada Koljenovic, NL</b> Evolving radiation oncology practice for the management of unknown primary cancers <b>Vincent Grégoire, FR</b>
17:45 -19:00	WELCOME RECEPTION

## FRIDAY 4 MARCH 2022

09:00 -09:30	<b>KEYNOTE LECTURE 3</b> <b>New concepts in the management of oligometastatic disease</b> <i>Chairs: P. Bossi, IT &amp; S. Tribius, DE</i> <i>Speaker: Petr Szturz, CZ</i>
09:30 -10:00	<b>KEYNOTE LECTURE 4</b> <b>Intraoperative margin analysis</b> <i>Chairs: A. Dietz, DE &amp; K. Hunter, UK</i> <i>Speaker: Robert Baatenburg de Jong, NL</i>
10:00 -10:30	COFFEE BREAK
10:30 -11:30	<b>PROFFERED PAPERS 2</b>
11:30 -12:45	<b>SYMPOSIUM 3</b> <b>The role of IO in the curative setting</b> <i>Chairs: JP. Machiels, BE &amp; P. Gorphe, FR</i> IO prior to local treatment <b>Lotje Zuur, NL</b> Why combining radiotherapy and IO is challenging <b>Kevin Harrington, UK</b> The role of IO in the adjuvant setting <b>Lisa Licitra, IT</b>
12:45 -14:15	LUNCH AND SATELLITE SYMPOSIUM
14:15 -15:15	<b>INTERACTIVE TUMOR BOARD SESSION</b> <b>Sinonasal cancer</b> <i>Chair: H. Mehanna, UK</i> <i>Panellists: P. Nicolai, IT; D. Thomson, UK; E. Marbaix, BE; R. Mesia, ES; R. Maroldi, IT</i>
15:15 -15:45	PROFFERED PAPERS 3
15:45 -16:15	COFFEE BREAK
16:15 -17:30	<b>SYMPOSIUM 4</b> How to manage frail patients in the localized setting <i>Chairs: J. Guigay, FR &amp; S. Hosal, TR</i> <i>Assessment of frail patients in daily practice</i> <b>Cécile Mertens, FR</b> <i>Which concomitant treatment with radiotherapy for patients unfit for cisplatin</i> <b>Irene Brana, ES</b> <i>Long term quality of life in Head and Neck Cancer survivors</i> <b>Irma Verdonck-de Leeuw, NL</b>



# Awards

## SATURDAY 5 MARCH 2022

	<b>KEYNOTE LECTURE 5</b>
08:30 - 09:00	<b>Update on the role of de-escalation in HPV driven disease</b> <i>Chairs: A. Mäkitie, FI &amp; K. Skladowski, PL</i> <i>Speaker: Sue Yom, US</i>
	<b>SYMPOSIUM 5</b>
09:00 - 10:15	<b>Innovative techniques to improve functional outcomes</b> <i>Chair: E.M. Ozsahin &amp; G. Sanchez Aniceto</i> New data on proton therapy for Head and Neck Cancers <b>Cai Grau, DK</b> Advances in robotic surgery <b>Christopher Holsinger, US</b> MR Linac based treatment <b>Houda Bahig, CA</b>
10:15 - 10:45	COFFEE BREAK
	<b>INTERACTIVE TUMOUR BOARD</b>
10:45 - 11:45	<b>Two cases on larynx/hypopharynx tumours TBC</b> <i>Chair: M. Evans, UK</i> <i>Panellists: G. Succo, IT; C. Paterson, UK; A. Castro, PT; R. Maroldi, IT</i>
	<b>DEBATE</b>
11:45 - 12:45	<b>This house believes that follow-up should be symptom based</b> <i>Chairs: P. Blanchard, FR; W. Golusinski, PL; S. Oosting, NL</i> Voting <i>For the motion: Hisham Mehanna, UK</i> <i>Against the motion: Hans Langendijk, NL</i> Voting <i>For the motion: Olgun Elicin, CH</i> <i>Against the motion: Haitham Mirghani, FR</i> Voting
12:45 - 13:00	<b>CONCLUDING REMARKS</b> <i>P. Blanchard (ESTRO); W. Golusinski (EHNS); S. Oosting (ESMO)</i>

### ORAL COMMUNICATION AWARD | € 1000

An Oral communication award will be given to the best abstract selected as proffered paper.

The award will be selected by the ICHNO-ECHNO 2022 Scientific Committee.

#### Criteria for selection

Only abstracts accepted as proffered paper for the ICHNO-ECHNO 2022 conference will be considered for the award.

#### How to apply

No application is needed. You are automatically considered if your abstract is accepted. The award will be handed out during the closing remarks of the conference on Saturday, 5 March 2022.

### POSTER AWARD | € 1000

A Poster award will be given to the best abstract selected for the conference as poster presentation.

The award will be selected by the ICHNO-ECHNO 2022 Scientific Committee.

#### Criteria for selection

Only abstracts accepted for poster presentation for the ICHNO-ECHNO 2022 conference will be considered for the award

Posters are evaluated on (in decreasing order of importance): the scientific value of the data; the clarity of the presentation; and the visual quality of the poster layout

Priority will be given to posters from young investigators.

#### How to apply

No application is needed. You are automatically considered if your abstract is accepted. The award will be handed out during the closing remarks of the conference on Saturday, 5 March 2022.



# General Information

## UPDATED INFORMATION

Please consult the ESTRO website on a regular basis for updated information.

## CALL FOR ABSTRACTS

Abstracts must be submitted online through the ESTRO website which hosts an online abstract submission form.


**Deadline for abstract submission is 13 October 2021.**

## CME ACCREDITATION

The conference organisers will apply for CME accreditation with the European Accreditation Council for Continuing Medical Education (EACCME). Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credits TM. Information on the process to convert EACCME credit to AMA credit can be found at <https://www.ama-assn.org/education/ama-pra-credit-system/agreement-european-union-medical-specialties-uems>. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of The Royal College of Physicians and Surgeons of Canada. ESTRO will also apply for ESMO-MORA Category 1 points.

## POSTERS

A poster area will be available at any time during the conference hours.





# ESTRO

## ESTRO

European Society  
for Radiotherapy & Oncology

Rue Martin V, 40  
1200 Brussels  
Belgium

Follow us on    

[WWW.ESTRO.ORG](http://WWW.ESTRO.ORG)

